INFLUENCE OF CARDIOVASCULAR RISK FACTORS ON THE LEVELS OF TOLL-LIKE RECEPTORS 2 AND VASCULOENDOTHELIAL GROWTH FACTOR IN PATIENTS WITH RHEUMATOID ARTHRITIS
Introduction. Rheumatoid arthritis (RA) is a disease with high prevalence and disability rates. Cardiovascular pathology is one of the most frequent comorbid pathologies in RA patients. Activation of angiogenesis in the synovium plays a key role in pathogenetic mechanism of RA. Cardiovascular pathology сan influence on inflammatory and angiogenic processes with the participation of toll-like receptors 2 (TLR2) and vasculoendothelial growth factor (VEGF).
The aim of the study – to determine the effect of cardiovascular risk factors on the level of TLR2 and VEGF in the blood of RA patients.
Research Methods. In the study 67 patients with RA (73.1 % women), aged (45.2±8.75) years and 25 healthy controls age-matched were enrolled. The diagnosis of RA was established by ACR/EULAR criteria 2010. Serum TLR2 and VEGF levels were determined by enzyme immunoassay (Cloud-Clone Corp., USA). The study was conducted in compliance with bioethical standards. Statistical processing of the results was performed in the STATISTICA 6.0 package.
Results and Discussion. In RA patients, TLR2 and VEGF levels were significantly 2.78 and 2.69-times higher, respectively (p<0.001) than in the control group. In patients with DAS28-ESR >5.1, TLR2 and VEGF levels were higher (1.3-1.4 times) than in patients with moderate disease activity (DAS28-ESR 3.2-5.1). Among the seropositive by ACCP subjects, levels of TLR2 were significantly higher. Increased levels of TLR2 and VEGF in RA patients were associated with concomitant hypertension and obesity, though no connection with age, gender, dyslipidemia, and smoking was found.
Conclusions. Among RA patients serum levels of TLR2 and VEGF were higher, compared to the control. Increasing of TLR2 level associated with seropositivity by ACCP and high disease activity, and VEGF elevation associated with comorbid arterial hypertension and high body mass index.
Boo, S., Oh, H., Froelicher E.S., & Suh, C.H. (2017) Knowledge and perception of cardiovascular disease risk among patients with rheumatoid arthritis. PLoS One, 12 (4):e0176291. doi: 10.1371/journal.pone.0176291. [PubMed]
Liao, K.P. (2017) Cardiovascular disease in patients with rheumatoid arthritis. Trends Cardiovasc. Med., 27 (2), 136-140. doi: 10.1016/j.tcm.2016.07.006. [PubMed]
Castro, L.L., Lanna, C.С.D., Rocha, M.P., Ribeiro, A.L.P., & Telles, R.W. (2018). Recognition and control of hypertension, diabetes, and dyslipidemia in patients with rheumatoid arthritis. Rheumatol. Int., 38 (8), 1437-1442. doi: 10.1007/s00296-018-4084-3.
Mackey, R.H., Kuller, L.H., Deane, K.D., Walitt, B.T., Chang, Y.F., Holers, V.M., Robinson, W.H.,… & Moreland, L.W. (2015) Rheumatoid arthritis, anti-cyclic citrullinated peptide positivity, and cardiovascular disease risk in the women's health initiative. Arthritis Rheumatol., 67 (9), 2311-2322. doi: 10.1002/art.39198.
Mysnychenko, O.V. (2016). Rivni anhiopoetynu-2 i vaskuloendotelialnoho faktora rostu v krovi u khvorykh na hipertonichnu khvorobu z abdominalnym ozhyrinniam v dynamitsi 12-tyzhnevoi antyhipertenzyvnoi i hipolipidemichnoi terapii [Levels of angiopoietin-2 and vascular endothelial growth factor in the blood of patients with essential hypertension and abdominal obesity after 12 weeks of combined antihypertensive and lipid-lowering treatment]. Eksperymentalna i klinichna medytsyna – Experimental and Clinical Medicine, 70 (1), 84-88 [in Ukrainian].
Mohylnytska, L.A. (2017) Kontsentratsiia vaskuloendotelialnoho faktoru rostu v syrovattsi krovi khvorykh z arterialnoiu hipertenziieiu, shcho suprovodzhuietsia tsukrovym diabetom 2-ho typu, ozhyrinniam [Serum level of vegf in arterial hypertension with type 2 diabetes, obesity]. Visnyk problem biolohii i medytsyny – Bulletin of Problems of Biology and Medicine, 3 (141), 158-163 [in Ukrainian].
Wieczór, R., Wieczór, A.M., Gadomska, G., Stankowska, K., Fabisiak, J., Suppan, K., Pulkowski, G., …. & Rość, D. (2016). Overweight and obesity versus concentrations of VEGF-A, sVEGFR-1, and sVEGFR-2 in plasma of patients with lower limb chronic ischemia. J. Zhejiang Univ. Sci. B., 17 (11), 842-849. doi:10.1631/jzus.B1600009.
Aplin, A.C., Ligresti, G., Fogel, E., Zorzi, P., Smith, K., & Nicosia, R.F. (2014). Regulation of angiogenesis, mural cell recruitment and adventitial macrophage behavior by Toll-like receptors. Angiogenesis., 17(1):147-161. doi: 10.1007/s10456-013-9384-3.
McCarthy, C.G., Goulopoulou, S., Wenceslau, C.F., Spitler, K., Matsumoto, T., & Webb, R.C. (2014). Toll-like receptors and damage-associated molecular patterns: novel links between inflammation and hypertension. Am. J. Physiol. Heart Circ. Physiol., 306 (2), 184-196. doi:10.1152/ajpheart.00328.2013.
Holmes, L.Jr., Lim, A., & Comeaux, C.R. (2019). DNA methylation of candidate genes (ACE II, IFN-γ, AGTR 1, CKG, ADD1, SCNN1B and TLR2) in essential hypertension: a systematic review and quantitative evidence synthesis. Int. J. Environ. Res. Public. Health, 16 (23). E4829. doi: 10.3390/ijerph16234829.
Hetlanda, M.L., Christensenb, J., Lottenburgerc, T., Johansend, J.S., Svendsen, M. N., Hørslev-Petersenc, K., Nielsene, L. & Nielsen, H.J. (2008). Circulating VEGF as a biological marker in patients with rheumatoid arthritis? Preanalytical and biological variability in healthy persons and in patients. Disease Markers, 24, 1-10.
Voronkov, L.H., & Komarova, E.B. (2014). Vplyv sudynnoho endotelialnoho faktora rostu na kliniko-laboratorno-instrumentalni pokaznyky u khvorykh na revmatoidnyi artryt [Influence of vascular endothelial growth factor on the clinical-laboratory-instrumental parametrs in patients with rheumatoid arthritis]. Ukr. Revm. Zhurn. ‒ Ukrainian Rheumatological Journal, 57 (3), 91-93 [in Ukrainian].
Lee, Y.H., & Bae, S.C. (2018). Correlation between circulating VEGF levels and disease activity in rheumatoid arthritis: a meta-analysis. Z. Rheumatol., 77 (3), 240-248. doi: 10.1007/s00393-016-0229-5.
Houssen, M., El-Mahdy, R., & Shahin, D. (2014). Serum soluble toll-like receptor 2: a novel biomarker for systemic lupus erythematosus disease activity and lupus-related cardiovascular dysfunction. International Journal of Rheumatic Diseases, 19 (7), 685-692.